探索TLR激动剂作为COVID-19口服疫苗佐剂的研究
本研究提出一种口服疫苗制剂Vacform,由免疫调节剂CL097(TLR7/8激动剂)与SARS-CoV-2刺突蛋白共同包裹于葡聚糖颗粒(GPs)中。体外实验显示Vacform在特定细胞中诱导ROS、TNF-α、IL-6产生并刺激人PBMC增殖;C57BL/6小鼠先皮下免疫、后每两周口服加强两次, elicited 体液(血清IgG和黏膜sIgA)和细胞免疫应答,呈平衡的Th1/Th2/Th17免疫特征。结论认为GPs:CL097佐剂系统有前景,为后续剂量优化和攻毒模型研究奠定基础。
要点
- Vacform由CL097(TLR7/8激动剂)和SARS-CoV-2刺突蛋白包裹于葡聚糖颗粒组成。
- 小鼠先皮下免疫后每两周口服加强两次,诱导血清IgG和黏膜sIgA及细胞免疫应答。
- 观察到平衡的Th1/Th2/Th17免疫特征。
核心结论
- GPs:CL097佐剂系统在诱导针对SARS-CoV-2的免疫应答方面显示出前景,并为未来剂量反应优化和攻毒模型研究提供了基础。
研究设计与样本
- 体外细胞实验:检测Vacform在RAW 264.7细胞、人中性粒细胞、小鼠脾细胞和人PBMC中的免疫调节作用。
- 动物免疫研究:C57BL/6小鼠先皮下免疫,随后每两周口服加强两次Vacform。
主要发现
- Vacform在RAW 264.7细胞中诱导ROS产生,但在人中性粒细胞中未诱导ROS产生。
- 所测试浓度的Vacform未在RAW 264.7细胞中诱导NO产生。
- Vacform刺激小鼠脾细胞产生TNF-α和IL-6,但在RAW 264.7细胞中未观察到该效应。
- Vacform刺激人PBMC增殖。
- 小鼠免疫后 elicited 体液免疫(血清IgG和黏膜sIgA)和细胞免疫应答,呈平衡的Th1/Th2/Th17免疫特征。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The COVID-19 pandemic underscored the importance of advancing technologies that enable the rapid development and distribution of more effective vaccines when required. Since SARS-CoV-2 enters the body through the nasal mucosa, optimising the induction of secretory IgA (sIgA) production, a key component of the mucosal immune response, is essential. It has long been known that the induction of sIgA occurs when a vaccine is administered through mucosal surfaces and the immune responses initiated at one mucosal site can influence immune activity at other mucosal surfaces. Consequently, we propose an oral vaccine formulation (Vacform) comprising the immunomodulator CL097, a TLR7/8 agonist, and the SARS-CoV-2 spike protein, both encapsulated within glucan particles (GPs). The studies demonstrated that Vacform induced ROS production in RAW 264.7 cells but not in human neutrophils. The concentrations of Vacform tested did not induce NO production in RAW 264.7 cells. While Vacform stimulated the production of TNF-α and IL-6 in mouse spleen cells, this effect was not observed in RAW 264.7 cells. Finally, Vacform stimulated the proliferation of human PBMCs. Thus, its immunomodulatory properties were evident in specific cells under certain in vitro conditions. The Vacform was subsequently tested in vaccination studies. C57BL/6 mice were initially immunized subcutaneously, followed by two oral boosts with Vacform every two weeks. The Vacform elicited both, humoral (serum IgG and mucosal sIgA) and cellular immune responses. A balanced Th1/Th2/Th17 immune profile was observed. In conclusion, the GPs:CL097 adjuvant system shows promise for eliciting robust immune responses against SARS-CoV-2 and provides a foundation for future studies on dose-response optimization and challenge models.
引用
- Félix P, Melo AA, Costa JP, et al. Exploring TLR agonists as adjuvants for COVID-19 oral vaccines. Vaccine. 2025. PMID: 40184639. doi:10.1016/j.vaccine.2025.127078
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。